Table 1.
Patient characteristics in ER and/or PR positive population (by local assessment)
| Characteristic | N = 2642 |
|---|---|
| Age (years) | |
| Median (range) | 56 (25–77) |
| Tumour size (mm) | |
| Median (range) | 19 (1.2–130.) |
| Nodal status [N (%)] | |
| pN0 | 1554 (58.8) |
| pN1 | 930 (35.2) |
| pN2 | 122 (4.6) |
| pN3 | 36 (1.4) |
| Therapy [N (%)] | |
| Endocrine | 348 (13.0) |
| Chemotherapy randomization | 1970 (74.6) |
| Out of study | 324 (12.4) |
| RS result [N (%)] | |
| ≤11 | 459 (17.4) |
| 12–25 | 1544 (58.4) |
| > 25 | 550 (20.8) |
| Unknown | 89 (3.4) |
| Central hormone receptor status, [N (%)] | |
| ER positive | 2118 (89.7) |
| PR positive | 1751 (74.1) |
| ER and/or PR positive | 2202 (93.2) |
| ER and PR negative | 57 (2.4) |
| Unknown | 160 (6.8) |
| Central grade [N (%)] | |
| Grade 1 | 134 (5.1) |
| Grade 2 | 1636 (61.9) |
| Grade 3 | 825 (31.2) |
| Unknown | 47 (1.8) |
| Median Ki-67 (%) | 15 |
ER oestrogen receptor, PR progesterone receptor, RS recurrence score